

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

**SUPPLEMENTAL ANNOUNCEMENT TO THE CIRCULAR
OF THE COMPANY DATED 31 OCTOBER 2022**

Reference is made to the circular of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) dated 31 October 2022 (the “**Circular**”) in relation to, among other things, the Renewed Financial Services Agreement which is subject to Independent Shareholders’ approval pursuant to Chapter 14A of the Hong Kong Listing Rules. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The Board announces that, on 31 October 2022, it received an undertaking letter (the “**Undertaking Letter**”) from Fosun High Tech, the controlling shareholder of the Company, to the Company. Pursuant to the Undertaking Letter, Fosun High Tech has unconditionally and irrevocably undertaken that, during the service term of the Renewed Financial Services Agreement, it will:

1. maintain its effective control of Fosun Finance and ensure the proper and orderly operation of Fosun Finance;
2. use its best endeavors and take all reasonable measures to ensure that Fosun Finance will perform its obligations in respect of the financial services contemplated under the Renewed Financial Services Agreement; and
3. bear all losses resulting from any default in performance by Fosun Finance of its obligations under the Renewed Financial Services Agreement, including but not limited to the principal amount of and interest on the deposits placed by the Group with Fosun Finance and the relevant expenses incurred, within ten business days after the occurrence of such default.

No amendment has been made to the terms of the Renewed Financial Services Agreement entered into by the Company and Fosun Finance as a result of the Undertaking Letter, and the Board confirms that its recommendations as set out in the “Letter from the Board” of the Circular remains unchanged. The Company has also notified Yue Xiu Capital, the Independent Financial Adviser, and the Independent Board Committee of the above, both of whom have confirmed that the Undertaking Letter does not

change their respective conclusions and recommendations to the Independent Shareholders as to voting on the relevant resolution as set out in the Circular with respect to the transactions contemplated under the Renewed Financial Services Agreement (as respectively set out in the “Letter from the Independent Financial Adviser in respect of the Renewed Financial Services Agreement” and “Letter from the Independent Board Committee in respect of the Renewed Financial Services Agreement” of the Circular).

Save as disclosed above, all other information in the Circular remains unchanged. This announcement is supplemental to and should be read in conjunction with the Circular.

By Order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC

31 October 2022

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* For identification purpose only